Antibodies to protein but not glycolipid structures are important for host defense against by Meyer Sauteur, Patrick M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Antibodies to protein but not glycolipid structures are important for host
defense against
Meyer Sauteur, Patrick M; de Bruijn, Adrianus C J M; Graça, Catarina; Tio-Gillen, Anne P; Estevão,
Silvia C; Hoogenboezem, Theo; Hendriks, Rudi W; Berger, Christoph; Jacobs, Bart C; van Rossum,
Annemarie M C; Huizinga, Ruth; Unger, Wendy W J
Abstract: Antibody responses to Mycoplasma pneumoniae correlate with pulmonary M. pneumoniae
clearance. However, M. pneumoniae-specific IgG antibodies can cross-react with the myelin glycolipid
galactocerebroside (GalC) and cause neurological disorders. We assessed whether antiglycolipid antibody
formation is part of the physiological immune response to M. pneumoniae We show that antibodies
against M. pneumoniae proteins and glycolipids arise in serum of M. pneumoniae-infected children and
mice. Although antibodies to M. pneumoniae glycolipids were mainly IgG, anti-GalC antibodies were
only IgM. B-1a cells, shown to aid in protection against pathogen-derived glycolipids, are lacking in
Bruton tyrosine kinase (Btk)-deficient mice. M. pneumoniae-infected Btk-deficient mice developed M.
pneumoniae-specific IgG responses to M. pneumoniae proteins but not to M. pneumoniae glycolipids,
including GalC. The equal recovery from M. pneumoniae infection in Btk-deficient and wild-type mice
suggests that pulmonary M. pneumoniae clearance is predominantly mediated by IgG reactive with M.
pneumoniae proteins and that M. pneumoniae glycolipid-specific IgG or IgM is not essential. These data
will guide the development of M. pneumoniae-targeting vaccines that avoid the induction of neurotoxic
antibodies.
DOI: https://doi.org/10.1128/IAI.00663-18
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-161624
Journal Article
Published Version
Originally published at:
Meyer Sauteur, Patrick M; de Bruijn, Adrianus C J M; Graça, Catarina; Tio-Gillen, Anne P; Estevão,
Silvia C; Hoogenboezem, Theo; Hendriks, Rudi W; Berger, Christoph; Jacobs, Bart C; van Rossum,
Annemarie M C; Huizinga, Ruth; Unger, Wendy W J (2018). Antibodies to protein but not glycolipid
structures are important for host defense against. Infection and Immunity, 87(2):e00663-18.
DOI: https://doi.org/10.1128/IAI.00663-18
Antibodies to Protein but Not Glycolipid Structures Are
Important for Host Defense against Mycoplasma pneumoniae
Patrick M. Meyer Sauteur,a,b,c,d Adrianus C. J. M. de Bruijn,a Catarina Graça,a Anne P. Tio-Gillen,e,f Silvia C. Estevão,a
Theo Hoogenboezem,a Rudi W. Hendriks,g Christoph Berger,c,d Bart C. Jacobs,e,f Annemarie M. C. van Rossum,b
Ruth Huizinga,e Wendy W. J. Ungera
aLaboratory of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus MC-Sophia Children’s Hospital, University Medical Center, Rotterdam,
The Netherlands
bDepartment of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus MC-Sophia Children’s Hospital, University Medical Center, Rotterdam,
The Netherlands
cDivision of Infectious Diseases and Hospital Epidemiology, University Children’s Hospital Zurich, Zurich, Switzerland
dChildren’s Research Center, University Children’s Hospital Zurich, Zurich, Switzerland
eDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
fDepartment of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
gDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
ABSTRACT Antibody responses to Mycoplasma pneumoniae correlate with pulmo-
nary M. pneumoniae clearance. However, M. pneumoniae-speciﬁc IgG antibodies can
cross-react with the myelin glycolipid galactocerebroside (GalC) and cause neurologi-
cal disorders. We assessed whether antiglycolipid antibody formation is part of the
physiological immune response to M. pneumoniae. We show that antibodies against
M. pneumoniae proteins and glycolipids arise in serum of M. pneumoniae-infected
children and mice. Although antibodies to M. pneumoniae glycolipids were mainly
IgG, anti-GalC antibodies were only IgM. B-1a cells, shown to aid in protection
against pathogen-derived glycolipids, are lacking in Bruton tyrosine kinase (Btk)-
deﬁcient mice. M. pneumoniae-infected Btk-deﬁcient mice developed M.
pneumoniae-speciﬁc IgG responses to M. pneumoniae proteins but not to M.
pneumoniae glycolipids, including GalC. The equal recovery from M. pneumoniae
infection in Btk-deﬁcient and wild-type mice suggests that pulmonary M. pneu-
moniae clearance is predominantly mediated by IgG reactive with M. pneumoniae
proteins and that M. pneumoniae glycolipid-speciﬁc IgG or IgM is not essential.
These data will guide the development of M. pneumoniae-targeting vaccines that
avoid the induction of neurotoxic antibodies.
KEYWORDS Bruton tyrosine kinase, Guillain-Barré syndrome, Mycoplasma
pneumoniae, antibodies, autoimmunity, encephalitis, galactocerebroside, molecular
mimicry, pneumonia, vaccine
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia (CAP)and can trigger immune-mediated neurological complications such as Guillain-
Barre´ syndrome (GBS) and encephalitis (1). M. pneumoniae belongs to the smallest
self-replicating microorganisms, in terms of both cellular dimensions and genome size
(1). Unlike other bacteria, M. pneumoniae lacks a peptidoglycan layer and is therefore
naturally resistant to cell wall synthesis inhibitors such as -lactams. Macrolide antibi-
otics are recommended to treat M. pneumoniae infections in children (2). Extensive
macrolide use led to an alarming worldwide increase of macrolide-resistant M. pneu-
moniae (MRMP) strains, with rates of over 90% in some regions (3, 4). This emergence
of MRMP highlights the importance of implementing control strategies to prevent
infection, such as vaccines. Vaccination primarily induces antibody responses capable
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of neutralizing infection (5), but attempts to develop such vaccines against M. pneu-
moniae using inactivated bacteria in humans (reviewed in reference 6) and live atten-
uated strains in an animal model (7) have been complicated by limited efﬁcacy against
respiratory disease. No serious adverse effects and only mild local reactions were
reported in humans (6). However, it has been observed that reinfection or challenge
after vaccination with inactivated or live attenuated strains led to exacerbation of
disease in some anecdotal reports (8, 9) and animal experiments (10–14). Thus, to
develop optimal approaches to vaccination against M. pneumoniae, it is critical to
understand the immune mechanisms that contribute to resistance and immunopathol-
ogy of M. pneumoniae disease (15).
Immune responses against M. pneumoniae have been intensively investigated in
various animal models (e.g., see references 14 and 16–23). B cells are known to be
involved in pulmonary M. pneumoniae clearance (22, 24–27), and we recently showed
that in B cell-deﬁcient MT mice, M. pneumoniae infection led to chronic pulmonary
disease, characterized by higher histopathology scores (28). The observed compensa-
tory immune responses by both innate (granulocytes and monocytes) and adaptive
(CD4 and CD8 T cells) immune cells were not able to clear M. pneumoniae infection
in the absence of antibodies. In contrast, MT mice cleared M. pneumoniae infections
in the lungs when passively immunized with M. pneumoniae-speciﬁc immunoglobulin
G (IgG)-containing serum from infected wild-type (WT) mice 2 weeks after infection.
These ﬁndings indicate that B cells and M. pneumoniae-speciﬁc antibodies are crucial
for M. pneumoniae clearance in the lungs. Furthermore, these data suggest that they
may not contribute to immunopathology following primary infection given the less
severe pulmonary inﬂammation and better outcome in WT mice than in B cell-deﬁcient
MT mice (28).
M. pneumoniae is covered only with a cell membrane containing antigenic protein
and glycolipid structures (29). The membrane-anchored proteins at the cell pole form
an attachment structure important for initiating respiratory infection (30). Proteins
constitute over two-thirds of the M. pneumoniae membrane mass, with the rest being
membrane lipids, i.e., cholesterol, phospholipids, and glycolipids (29). M. pneumoniae
glycolipid subfractions have been shown to be highly immunogenic in mice and
humans (31). Their strong immunogenicity has been leveraged in diagnosis of M.
pneumoniae infection, whereby antigens derived from crude culture extracts that
contain large amounts of glycolipids were used in serological assays (32, 33). However,
because of cross-reactions with other mycoplasmas or Gram-negative bacteria, current
diagnostic assays focus on speciﬁc adhesion proteins (e.g., protein P1) rather than
glycolipids (32). Importantly, M. pneumoniae glycolipids also exhibit homology with
mammalian tissue compounds, which trigger cross-reactive antibodies that may target
cells of multiple host organ systems (34). GBS and encephalitis constitute the most
common and severe neurological diseases of M. pneumoniae extrapulmonary manifes-
tations in which an underlying postinfectious antibody-mediated process has been
proposed (33). In fact, it has been shown that galactocerebroside (GalC)-speciﬁc
antibodies bind to a lipid structure present in M. pneumoniae, indicative of molecular
mimicry between the major myelin glycolipid GalC and M. pneumoniae (35).
We recently showed that both IgM and IgG anti-GalC antibodies are present in the
serum of GBS patients and that the presence of anti-GalC IgG correlates with GBS (36).
Anti-GalC IgM was also found in 18% of anti-M. pneumoniae-seropositive control
patients without neurological diseases (36). Interestingly, all anti-GalC IgM-positive
individuals within this control cohort were children. This raises the question of whether
the formation of antibodies to M. pneumoniae glycolipids is part of the physiological
immune response and necessary to clear M. pneumoniae in children.
Antibody responses against glycolipids are thought to be driven by B-1a cells,
splenic marginal zone B cells, and nodal marginal zone B cells (i.e., thymus independent
[TI]) or by the help of natural killer T (NKT) cells (i.e., thymus dependent [TD]) (37–40).
An important role for B-1a cells in producing antibodies to pathogen-derived glycolipid
structures has been shown for Mycobacterium tuberculosis and Francisella tularensis
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(41–43). Interestingly, priming of Bruton tyrosine kinase-deﬁcient (Btk) mice with F.
tularensis-derived glycolipids did not result in protection against a lethal challenge with
an F. tularensis live vaccine strain (44). The lack of a protective antibody response in the
Btk-deﬁcient mice was attributed to the absence of B-1a cells (44, 45). Whether TI B cell
responses, and in particular B-1a cells, are also important for protection against M.
pneumoniae infection is unknown.
We set out to investigate in children which antigenic structures of M. pneumoniae
are recognized by antibodies, using a well-deﬁned cohort of children with CAP diag-
nosed with M. pneumoniae infection. Furthermore, employing WT and Btk mice, we
unraveled the role of TI B cell responses in the resolution of pulmonary M. pneumoniae
infection.
RESULTS
IgM but not IgG to GalC is induced during M. pneumoniae infection in children.
In light of our previous ﬁndings (36), we assessed whether anti-GalC IgM develops in all
children with M. pneumoniae CAP. To this end, we examined the serum of children with
M. pneumoniae CAP for the presence of anti-GalC antibodies by an enzyme-linked
immunosorbent assay (ELISA), and M. pneumoniae-negative asymptomatic healthy
control (HC) children were tested as controls. We detected anti-GalC IgM at signiﬁcantly
higher levels in sera of children with M. pneumoniae CAP than in sera of HC children
(Fig. 1A). Moreover, anti-GalC IgG was detectable only at very low levels in both children
with M. pneumoniae CAP and HC children (Fig. 1B). These ﬁndings conﬁrm and extend
previous observations that during childhood, M. pneumoniae CAP IgM against GalC
develops, whereas anti-GalC IgG does not.
IgM and IgG recognizeM. pneumoniae protein and glycolipid structures during
M. pneumoniae infection in humans. In addition to the antiglycolipid response to
GalC, we next investigated the antibody response against the complete M. pneumoniae
glycolipid as well as M. pneumoniae protein fractions. First, M. pneumoniae proteins and
glycolipids were separated from M. pneumoniae cultures using chloroform-methanol
(MeOH) extraction (2:1, vol/vol). The separation of proteins and glycolipids from the M.
pneumoniae lysate was analyzed by SDS-PAGE followed by silver staining (Fig. 1C) and
by thin-layer chromatography (TLC) followed by orcinol staining (Fig. 1D), respectively.
The reactivity and kinetics of M. pneumoniae-speciﬁc IgM and IgG antibodies toward
these structures were subsequently determined with an ELISA. To this end, we incu-
bated sera of children with M. pneumoniae CAP with either M. pneumoniae glycolipid
or M. pneumoniae protein fractions and an M. pneumoniae lysate as a control (referred
to as total M. pneumoniae). As for total M. pneumoniae, a speciﬁc antibody response of
both IgM and IgG isotypes against M. pneumoniae proteins and glycolipids could be
detected in allM. pneumoniae CAP patients within 9 days after the onset of the ﬁrst CAP
symptoms and peaked at around 1 month (20 to 35 days) (Fig. 1E to G). The speciﬁc IgM
and IgG response returned to baseline values around 3 months after the onset of CAP
symptoms. Analysis of IgG subclasses revealed that both IgG1 and IgG2 subclasses were
present in the anti-M. pneumoniae glycolipid IgG pool (Fig. 1H). These ﬁndings show
that the human IgM and IgG response to M. pneumoniae is directed against both M.
pneumoniae glycolipids and M. pneumoniae proteins.
IgG against glycolipids also predominates during M. pneumoniae infection in
mice. We previously showed that passive immunization of B cell-deﬁcient MT mice
with serum of WT mice containing M. pneumoniae-speciﬁc IgG enabled MT mice to
clear pulmonary M. pneumoniae infection (28). In fact, the detection of M. pneumoniae-
speciﬁc IgG in bronchoalveolar lavage ﬂuids (BALFs) correlated with bacterial clearance
in the lungs of MT recipient mice after WT serum transfer. Here, we demonstrate that
upon M. pneumoniae infection, antibodies are generated against both M. pneumoniae
protein and glycolipid structures. However, it is unclear whether both the anti-M.
pneumoniae protein and glycolipid antibodies are important for clearance of M. pneu-
moniae from the lungs. To evaluate this, we examined pulmonary M. pneumoniae
Target and Role of Antibodies to M. pneumoniae Infection and Immunity
February 2019 Volume 87 Issue 2 e00663-18 iai.asm.org 3
 o
n
 February 4, 2019 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
FIG 1 The antibody response induced by pulmonary M. pneumoniae infection in children is directed against GalC and M. pneumoniae protein and glycolipid
fractions. (A and B) The presence of antigalactocerebroside (anti-GalC) IgM (A) and anti-GalC IgG (B) in serum of children with M. pneumoniae (Mp)
community-acquired pneumonia (CAP) and healthy controls (HC) was determined by an ELISA. Sera of children with M. pneumoniae CAP were obtained at a
median of 34 days (interquartile range, 30 to 42 days) after the onset of symptoms (n  5). Dots represent data for individual children, and the horizontal line
in each graph represents the median. OD, optical density. (C) Total M. pneumoniae and puriﬁed M. pneumoniae protein fractions were analyzed by SDS-PAGE
followed by silver staining. Lane a, marker; lane b, total untreated M. pneumoniae M129 (125 ng); lane c, M. pneumoniae protein fractions (125 ng). (D) Thin-layer
chromatography (TLC) was used to analyze puriﬁed M. pneumoniae lipids. Lane a, cerium(IV) sulfate stain for total M. pneumoniae lipids; lane b, orcinol stain
for M. pneumoniae glycolipids. C, cholesterol; CE, cholesterol esters. (E to G) IgG and IgM levels in sera of children with M. pneumoniae CAP (n  5) at the
indicated time points after the onset of symptoms and reactivity against total M. pneumoniae (E) or the isolated M. pneumoniae proteins (F) and M. pneumoniae
glycolipids (G). Not all children had sera available at each time point beyond 30 days. Data are expressed as fold increases over controls (levels in sera of HC
(Continued on next page)
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infection in WT and Btk mice, as it has been shown that Btk mice cannot mediate
protective antibody responses to pathogen-derived glycolipid structures (43).
First, we investigated whether M. pneumoniae infection also results in a speciﬁc
antibody response against M. pneumoniae proteins and glycolipids in WT mice. We
therefore tested the reactivity and kinetics of murine serum antibodies of M.
pneumoniae-infected C57BL/6 WT mice against M. pneumoniae proteins or glycolipids
as for children with M. pneumoniae CAP. Consistent with our data from children, a
speciﬁc antibody response of both IgM and IgG isotypes against M. pneumoniae
proteins and glycolipids could be detected in all mice within 7 days postinfection (p.i.)
and peaked at around day 28 p.i. (Fig. 2A to C). These ﬁndings in mice parallel the data
from children by demonstrating a speciﬁc antibody response targeting both M. pneu-
moniae proteins and glycolipids.
Furthermore, we determined whether anti-GalC IgM is also detectable during the
course of M. pneumoniae infection in mice. Sera of M. pneumoniae-infected WT mice,
isolated at 28 days p.i., were incubated with GalC. Indeed, compared to mock-infected
control WT mice, levels of IgM antibodies to GalC were high in M. pneumoniae-infected
WT mice, although signiﬁcance was not reached (P 0.19) (Fig. 2D). In agreement with
the data from children, anti-GalC IgG was detectable at equally very low levels after
pulmonary M. pneumoniae infection as in uninfected control WT mice (Fig. 2E).
FIG 1 Legend (Continued)
children; n  5). Control levels are indicated by a dashed line. The means  standard deviations (SD) are shown. (H) IgG subclasses against M. pneumoniae
glycolipids in children with M. pneumoniae CAP and HC children (serum samples as the ones used for panel A). Dots represent data for individual children. **,
P 0.01 (A, B, and H) (by a Mann-Whitney U test).
FIG 2 Antibody response against GalC and M. pneumoniae protein and glycolipid fractions during pulmonary M. pneumoniae
infection in mice. (A to C) IgG and IgM levels in sera of M. pneumoniae-infected C57BL/6 WT mice at the indicated time points
postinfection (p.i.) and reactivity against total M. pneumoniae (A) or M. pneumoniae proteins (B) and M. pneumoniae glycolipids (C).
Data are expressed as fold increases over controls (i.e., levels in sera of mock-infected control mice). Data for control levels are
indicated by a dashed line. The means  SD are shown (n  6 to 12 mice/time point). (D and E) Presence of anti-GalC IgM (D)
and absence of anti-GalC IgG (E) in sera of M. pneumoniae-infected and mock-infected mice obtained at 28 days p.i. (n  6). Dots
represent data for individual mice, and the horizontal line in each graph represents the median.
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IgG against M. pneumoniae proteins but not M. pneumoniae glycolipids is
crucial to resolve M. pneumoniae infection in mice. We next evaluated whether a
potential reduction in antiglycolipid antibodies in Btk mice affects M. pneumoniae
clearance from the lungs. We thus compared Btk mice with WT mice in terms of the
outcomes of M. pneumoniae infection and antiglycolipid antibody responses. Surpris-
ingly, CFU counts of M. pneumoniae in BALF of Btkmice were not different from those
in infected WT mice (Fig. 3A). Btk mice showed even better control of pulmonary
infection than WT mice at day 3 p.i. Nevertheless, both WT and Btk mice were able to
clear M. pneumoniae within 42 days. Analysis of serum antibodies revealed that M.
FIG 3 IgG against M. pneumoniae proteins but not M. pneumoniae glycolipids is crucial to resolve M. pneumoniae infection in mice. WT C57BL/6 mice (n  6
to 12 mice/time point) and Btk mice (n  6 to 12 mice/time point) were infected intranasally with M. pneumoniae. Control WT mice received SP4 medium
alone. Dots represent data for individual mice, and the horizontal lines represent the medians. (A to C) At the indicated time points, bacterial loads in BALF
(A) and serum levels of M. pneumoniae-speciﬁc IgM (B) and IgG (C) were determined. Bacterial loads are expressed as median CFU per milliliter with interquartile
ranges. AU, arbitrary units. (D) Avidity index of IgG against M. pneumoniae proteins at day 42 p.i. The bars represent the means  SD. (E and F) Serum levels
of M. pneumoniae-speciﬁc IgM (E) and IgG (F) against total M. pneumoniae (gray and black) or the separated M. pneumoniae proteins (light red and red) and
M. pneumoniae glycolipids (light blue and blue) in sera of M. pneumoniae-infected C57BL/6 WT mice (circles) and Btk mice (triangles) and additionally IgG in
sera of CD19-hBtk mice (diamonds) at day 14 p.i. *, P 0.05; **, P 0.01; ***, P 0.001 (determined by a Kruskal-Wallis test with Dunn’s post hoc
multiple-comparison test [A to C, E, and F] or Welch’s t test [D]).
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pneumoniae-speciﬁc antibody levels increased over time in both WT and Btk mice,
which were much more pronounced for IgG than for IgM, but the levels in Btk mice
were signiﬁcantly lower than those in WT mice (Fig. 3B and C). The same pattern was
observed for total IgG and IgM antibody levels in Btkmice (data not shown). Although
Btk mice contained lower IgG levels after M. pneumoniae infection, the avidity index
of IgG antibodies against M. pneumoniae-derived proteins was not different from that
in WT mice (Fig. 3D).
The increases in levels of IgM against M. pneumoniae proteins or glycolipids com-
pared to controls were similar between WT and Btk mice (Fig. 3E). Also, comparable
IgG responses to M. pneumoniae proteins were measured in sera from WT and Btk
mice (Fig. 3F, left). In contrast, the IgG response to M. pneumoniae glycolipids in Btk
mice was strikingly different from that in WT mice: no IgG antibodies against M.
pneumoniae glycolipids were detected (Fig. 3F, middle). The generation of IgG anti-
bodies against M. pneumoniae glycolipids was partially restored in CD19-hBtk mice (Fig.
3F, right), in which Btk is selectively rescued in B cells and is lacking only in myeloid cells
(46). These ﬁndings could be corroborated by measuring IgM and IgG toM. pneumoniae
proteins or glycolipids of WT and Btk mice in BALF. As previously observed (28), we
found very low levels of IgM, which were comparable between mouse strains for M.
pneumoniae proteins and glycolipids (Fig. 4A). As in serum, the IgG antibody levels to
M. pneumoniae glycolipids in Btk mice were signiﬁcantly lower than those in BALF of
WT mice and close to control levels (Fig. 4B). Serum anti-GalC IgM and IgG antibodies
were not produced by M. pneumoniae-infected Btk mice (Fig. 5).
DISCUSSION
Here, we extend previous ﬁndings on the essential role of M. pneumoniae-speciﬁc
IgG antibodies in pulmonary clearance (27, 28) by demonstrating that IgG antibodies
FIG 4 Local antibody response against M. pneumoniae protein and glycolipid fractions during pulmonary
M. pneumoniae infection in mice. Shown are BALF levels of M. pneumoniae-speciﬁc IgM (A) and IgG (B)
against total M. pneumoniae (gray and black) or the separated M. pneumoniae proteins (light red and red)
andM. pneumoniae glycolipids (light blue and blue) ofM. pneumoniae-infected C57BL/6 WT mice (circles)
(n  6) and Btk mice (triangles) (n  6) at day 14 p.i. Dots represent data for individual mice, and the
horizontal lines represent the medians. *, P 0.05; ***, P 0.001 (by a Kruskal-Wallis test with Dunn’s
post hoc multiple-comparison test).
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reactive with M. pneumoniae proteins alone seem to be sufﬁcient to clear M. pneu-
moniae in the lungs. We show that Btk mice clear M. pneumoniae infections compa-
rably to WT mice but do not generate a detectable humoral response toM. pneumoniae
glycolipids. These data also indicate that even low levels of M. pneumoniae protein-
speciﬁc IgG antibodies, albeit of sufﬁcient avidity, are able to mediate protection in the
lungs of Btk mice. Notably, Btk mice showed better control of pulmonary M.
pneumoniae infection than did WT mice at day 3 p.i. At this time point, signiﬁcantly
higher numbers of alveolar macrophages and NK cells were observed in lungs of Btk
mice than in WT mice (data not shown). B-1a cells have been shown to inhibit
macrophage-NK cell cross talk (47). The observed improved control of M. pneumoniae
replication in Btk mice may thus result from the absence of B-1a cells in these mice
(48, 49). We speculate that in WT mice, M. pneumoniae triggers the activation of B-1a
cells, which dampen M. pneumoniae clearance by inhibiting the activation of macro-
phages and/or NK cells. However, the inhibitory effect of B-1a cells is not as sufﬁcient
and/or long lasting, as M. pneumoniae is cleared from the lungs of WT mice within 4 to
6 weeks.
In addition to their important role in the clearance of M. pneumoniae in the lungs,
the induced M. pneumoniae protein-speciﬁc antibodies may also prevent reinfection or
reduce horizontal transmission. It was shown previously that antibodies from M.
pneumoniae-immunized guinea pigs targeting recombinant P1 and P30 adhesion
proteins inhibit the adherence of M. pneumoniae to human bronchial epithelial cells in
vitro (23). This indicates that anM. pneumoniae-speciﬁc vaccine for high-risk individuals,
i.e., schoolchildren and elderly people, should aim at inducing potent antibodies
directed against M. pneumoniae proteins. The data obtained with Btk mice suggest
that such a vaccine may even be effective in children with common variable immuno-
deﬁciency or hypogammaglobulinemia with reduced B cells, who have been reported
to be at an increased risk for M. pneumoniae pulmonary disease and/or extrapulmonary
manifestations (50–54).
Our data reveal that the humoral response against M. pneumoniae glycolipids is
redundant for the clearance of M. pneumoniae in the lungs of mice. This is rather
unexpected given the fact that levels of IgG against M. pneumoniae glycolipids were
higher than those against M. pneumoniae proteins and were of the IgG1 and IgG2
subclasses, which indicates potential neutralization and complement-dependent killing
of M. pneumoniae. Furthermore, within the pool of M. pneumoniae glycolipid-speciﬁc
IgM antibodies, some also bear cross-reactivity to self-tissue (i.e., GalC-like M. pneu-
moniae structure [33]). Indeed, we previously elucidated cross-reactivity between M.
pneumoniae and GalC and associated the presence of anti-GalC IgG with GBS triggered
by M. pneumoniae (36). However, here, we conﬁrmed that in the absence of neurop-
FIG 5 Comparison of the antibody responses against GalC between WT and Btkmice during pulmonary
M. pneumoniae infection. Shown are serum anti-GalC IgM (A) and anti-GalC IgG (B) responses of M.
pneumoniae-infected WT mice (n  5 mice) and Btk mice (n  4 mice) at 42 days p.i. ***, P 0.001 (by
a Mann-Whitney U test).
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athy, anti-GalC IgG was not formed during pulmonary M. pneumoniae infection. In
contrast, the formation of anti-GalC IgM, which seems not to inﬂict neurotoxicity, was
part of the physiological response.
Cross-reactivity of M. pneumoniae glycolipid-speciﬁc antibodies with self-tissue,
causing immunopathology, may be one possible reason why BALB/c mice vaccinated
with live attenuated M. pneumoniae developed more-severe pulmonary disease follow-
ing infection with wild-type M. pneumoniae (10). This could also be observed after
repeated infections with wild-type M. pneumoniae in BALB/c mice but not in C57BL/6
mice (11). It is known that not only rechallenge after vaccination but also primary M.
pneumoniae infection of BALB/c mice led to worse pulmonary inﬂammation than in
C57BL/6 mice (18), which simply reﬂects heterogeneity in susceptibility to M. pneu-
moniae infection in mice as in humans (1, 18).
The observation that M. pneumoniae glycolipid-speciﬁc antibodies are not gener-
ated in Btk mice suggests that the production of lipid-speciﬁc antibodies may be, at
least in part, mediated by B-1a cells, as these cells are lacking in Btk mice (48, 49).
Notably, in contrast to M. pneumoniae infection, antibodies to pathogen-derived gly-
colipid structures were shown previously to protect against infections with M. tuber-
culosis and F. tularensis (41–43). Immunization of Btkmice with F. tularensis glycolipids
did not result in protection against a lethal challenge with an F. tularensis live vaccine
strain, which was attributed to the absence of B-1a cell-produced glycolipid-speciﬁc
antibodies (44, 45). Apart from TI B cell responses, a potential role for nonclassical T
helper cells, the NKT cells, in the production of M. pneumoniae lipid antibodies cannot
be ruled out.
In fact, cross-linking of the B cell receptor (BCR) on B-1a cells by lipid-based antigens
leads to an innate-like polyreactive IgM response (so-called natural antibody response)
important for early protection against mucosal pathogens (37). B-1 cells can also
provide long-lasting TI IgM memory (43, 55). One might speculate that the presence of
anti-GalC IgM but not IgG after M. pneumoniae infection in children and mice indicates
that a GalC-like structure in M. pneumoniae triggered speciﬁcally B-1a cells to produce
natural IgM. Natural antibodies are characterized by low afﬁnity (37, 56), which may
explain whyM. pneumoniae glycolipid-speciﬁc antibodies were redundant for clearance
of pulmonary M. pneumoniae infection. Apart from afﬁnity, the level of anti-GalC IgG
may be critical for the initiation of M. pneumoniae-associated neurological disease. It is
possible that low levels of GalC IgG are removed from the circulation by target-
mediated clearance (57). Interestingly, B-1a cells triggered by glycolipid antigens can
also undergo activation-induced deaminase-dependent class switching (43). However,
this is a rare event (43), as is the development of GBS followingM. pneumoniae infection
(36). Thus, these ﬁndings further support the hypothesis that a GalC-likeM. pneumoniae
structure may trigger B-1a cells, which undergo class switching in rare cases, and
produce potentially neurotoxic anti-GalC IgG. However, the exact events that lead to
the induction of autoreactive B cells and anti-GalC IgG remain to be identiﬁed.
In conclusion, our data extend previous ﬁndings on the essential role of M.
pneumoniae-speciﬁc antibodies in clearing M. pneumoniae from the lungs (27, 28) by
suggesting that the IgG response to M. pneumoniae-derived proteins is important for
pulmonary clearance of M. pneumoniae. The ﬁnding that M. pneumoniae glycolipid-
speciﬁc IgM and IgG antibodies are redundant for M. pneumoniae clearance but can
also target the myelin glycolipid GalC is of importance not only for the understanding
of M. pneumoniae-associated immune-mediated diseases but also for the design of M.
pneumoniae-targeting vaccines. Based on our results, such vaccine formulations should
include M. pneumoniae protein antigens rather than M. pneumoniae lipids, thereby
avoiding the induction of potential autoimmune antiglycolipid antibodies.
MATERIALS AND METHODS
Mice. C57BL/6 mice were purchased from Charles River Laboratories and used at 8 to 12 weeks of
age. Btk mice (Btk/ or Btk/Y, on the C57BL/6 background [48]) and CD19-hBtk mice (backcrossed on
Btk C57BL/6 mice for 10 generations [46]) were bred and housed in the animal facilities of the
Erasmus MC under speciﬁc-pathogen-free conditions. All experiments were conducted according to
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Dutch guidelines for animal experimentation and approved by the Animal Experiments Committee of the
Erasmus MC, Rotterdam, The Netherlands (protocol numbers 103-13-05 and 103-14-02).
Patients. Children with CAP and asymptomatic controls, admitted for a planned elective surgical
procedure, from 3 to 18 years of age were enrolled from 1 May 2016 to 30 April 2017 during a CAP study
at the University Children’s Hospital Zurich (P. M. Meyer Sauteur, unpublished data). Diagnosis was based
on the detection of M. pneumoniae DNA in pharyngeal swab specimens by PCR, speciﬁc serum IgM
antibodies by an ELISA, and circulating IgM antibody-secreting cells by an enzyme-linked immunospot
(ELISpot) assay (Meyer Sauteur, unpublished). Asymptomatic controls tested negative for M. pneumoniae
by PCR and serum IgM. Sera of these M. pneumoniae-positive CAP patients and M. pneumoniae-negative
asymptomatic controls were used in this study, since no further information about respiratory disease
characteristics was available from previous M. pneumoniae-seropositive controls without neurological
diseases (36), and M. pneumoniae infection can present with a wide range of respiratory tract symptoms
apart from CAP. The study was approved by the ethics committee of the Canton Zurich, Switzerland
(BASEC number 2016-00148). Written informed consent was obtained from all parents and from children
above the age of 14 years.
Bacteria. M. pneumoniae reference strain M129 (subtype 1; ATCC 29342) was cultured as previously
described (28).
Infection. Mice were inoculated intranasally with 1 109 CFU of M. pneumoniae M129 diluted in
50 l SP4 medium. Control mice were inoculated with 50 l SP4 medium.
M. pneumoniae quantiﬁcation. The presence of M. pneumoniae was detected by either PCR or
culture of BALF on SP4 agar plates (58).
Lipid extraction. Lipids were extracted from the M. pneumoniae M129 culture by the addition of
chloroform-methanol-water (2:1:1, vol/vol/vol). After a 1-h incubation at 4°C, the mixture was vortexed
and centrifuged at 2,000 g for 1 min. After repeating the extraction procedure, cells were sonicated for
30 min and centrifuged at 10,000  g for 5 min. Lipid extracts contained in the chloroform layer were
pooled and evaporated under nitrogen. Lipids were dissolved in ethanol, and extraction was veriﬁed by
the Liebermann-Burchard reaction. The puriﬁcation of M. pneumoniae glycolipids was conﬁrmed by TLC.
Here, extracted lipids (5 g) were applied to a silica glass plate (Merck Millipore) after activation for 2 h
at 110°C. The TLC plate was developed using CHCl3–MeOH–Milli-Q (60:35:8, vol/vol/vol). Total lipids were
visualized by using 10% cerium(IV) sulfate in 15% H2SO4, and glycolipids were visualized by using 0.1%
orcinol in 5% H2SO4, with heating up to 110°C.
Protein extraction. After delipidation of the M. pneumoniae lysate by chloroform-methanol-water
(2:1:1, vol/vol/vol) extraction, cold acetone was added to the aqueous (upper) layer and the insoluble
interface, followed by incubation at 4°C for 2 h. Proteins were collected by centrifugation at 10,000  g
for 5 min. Pellets were washed twice with acetone, air dried on ice, and dissolved in 4 M urea–250 mM
ammonium bicarbonate. The protein concentration was determined by a bicinchoninic acid assay.
Additionally, proteins (125 ng) were analyzed by SDS-PAGE, followed by silver staining (Merck).
Quantiﬁcation ofM. pneumoniae-speciﬁc antibodies againstM. pneumoniae antigens and GalC.
To assess the presence of speciﬁc antibodies against total M. pneumoniae, M. pneumoniae proteins and
glycolipids, and GalC, 96-well half-area polystyrene plates (Corning Costar) were coated overnight at 4°C
with an M. pneumoniae lysate (0.5 g) (28) or M. pneumoniae proteins (normalized to 1 ng adhesion
protein P1 per well present in both total M. pneumoniae and M. pneumoniae protein fractions) in a
100 mM sodium carbonate-bicarbonate buffer (pH 9.6) containing 1 M urea or with M. pneumoniae
glycolipids (normalized to 0.6 g cholesterol per well present in both total M. pneumoniae and M.
pneumoniae glycolipid fractions) and GalC (900 pmol) dissolved in ethanol. Nonspeciﬁc binding was
blocked using phosphate-buffered saline (PBS)–1% bovine serum albumin (BSA) (Sigma). Serum samples,
diluted in PBS–0.1% BSA, and undiluted BALF samples were added and incubated overnight at 4°C.
Bound antibodies were detected by the addition of horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgM or rabbit anti-mouse IgG (Thermo Scientiﬁc), biotinylated goat anti-human IgM with
HRP-conjugated streptavidin (Thermo Scientiﬁc), or HRP-conjugated rabbit anti-human IgG (Invitrogen)
and IgG1 to -4 (Sanquin). Reactions were visualized by using tetramethylbenzidine (TMB; Sigma) as the
substrate and stopped by using 1 M H2SO4. The optical density was measured at 450 nm with an ELISA
microplate reader (VersaMax). The results were analyzed by microplate data collection and analysis
software (VersaMax).
Statistical analysis. The R software environment (version 3.4.0) was used for statistical analysis.
Welch’s t test, the Mann-Whitney U test, and the Kruskal-Wallis test with post hoc Dunn’s multiple-
comparison test of selected pairs were used to determine statistical signiﬁcance. Statistical signiﬁcance
was deﬁned as a P value of 0.05.
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